- Home
- DALN vs CYTH Comparison
DALN vs CYTH Comparison
Compare DALN & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- CYTH
- Stock Information
- Founded
- DALN 1954
- CYTH 1990
- Country
- DALN United States
- CYTH United States
- Employees
- DALN N/A
- CYTH N/A
- Industry
- DALN Newspapers/Magazines
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- CYTH Health Care
- Exchange
- DALN Nasdaq
- CYTH Nasdaq
- Market Cap
- DALN 33.9M
- CYTH 31.9M
- IPO Year
- DALN 2008
- CYTH N/A
- Fundamental
- Price
- DALN $6.20
- CYTH $0.91
- Analyst Decision
- DALN
- CYTH Buy
- Analyst Count
- DALN 0
- CYTH 3
- Target Price
- DALN N/A
- CYTH $0.95
- AVG Volume (30 Days)
- DALN 41.5K
- CYTH 4.5M
- Earning Date
- DALN 03-05-2025
- CYTH 03-17-2025
- Dividend Yield
- DALN N/A
- CYTH N/A
- EPS Growth
- DALN N/A
- CYTH N/A
- EPS
- DALN N/A
- CYTH N/A
- Revenue
- DALN $128,286,000.00
- CYTH $870,725.00
- Revenue This Year
- DALN N/A
- CYTH N/A
- Revenue Next Year
- DALN N/A
- CYTH $24.49
- P/E Ratio
- DALN N/A
- CYTH N/A
- Revenue Growth
- DALN N/A
- CYTH N/A
- 52 Week Low
- DALN $2.98
- CYTH $0.55
- 52 Week High
- DALN $7.86
- CYTH $1.79
- Technical
- Relative Strength Index (RSI)
- DALN 44.32
- CYTH 53.59
- Support Level
- DALN $5.84
- CYTH $0.85
- Resistance Level
- DALN $6.65
- CYTH $1.45
- Average True Range (ATR)
- DALN 0.41
- CYTH 0.13
- MACD
- DALN -0.03
- CYTH -0.00
- Stochastic Oscillator
- DALN 28.52
- CYTH 22.83
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.